CN104825873A - Composition of EGCG and bamboo leaf flavonoid, preparation method and applications thereof - Google Patents

Composition of EGCG and bamboo leaf flavonoid, preparation method and applications thereof Download PDF

Info

Publication number
CN104825873A
CN104825873A CN201510228678.XA CN201510228678A CN104825873A CN 104825873 A CN104825873 A CN 104825873A CN 201510228678 A CN201510228678 A CN 201510228678A CN 104825873 A CN104825873 A CN 104825873A
Authority
CN
China
Prior art keywords
egcg
folium bambosae
bambosae flavone
preparation
flavone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510228678.XA
Other languages
Chinese (zh)
Other versions
CN104825873B (en
Inventor
张耿元
王保红
唐湘成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei Chang'e Biological Co ltd
Original Assignee
FUZHOU QIANZHENG PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUZHOU QIANZHENG PHARMACEUTICAL Co Ltd filed Critical FUZHOU QIANZHENG PHARMACEUTICAL Co Ltd
Priority to CN201510228678.XA priority Critical patent/CN104825873B/en
Publication of CN104825873A publication Critical patent/CN104825873A/en
Application granted granted Critical
Publication of CN104825873B publication Critical patent/CN104825873B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a composition containing EGCG and bamboo leaf flavonoid. The composition can be made into any pharmaceutically-acceptable dosage form, and the weight ratio of EGCG to bamboo leaf flavonoid is 0.05-2:1. The invention further discloses a preparation method of the composition and applications of the composition in preparation of drugs for protecting heart and cerebral vessels and tissues, relieving myocardial and cerebral ischemia, and reducing the happening rate of myocardial infarction, stroke, and cardiovascular diseases.

Description

The composition and method of making the same of EGCG and Folium Bambosae flavone and application
Technical field
The present invention relates to a kind of healthy product compositions, and its preparation method and application, the specifically compositions of EGCG and Folium Bambosae flavone, with and its preparation method and application.Healthy product compositions of the present invention, includes but not limited to medicine, medical food, health food or functional food, bread and cheese etc.
Background technology
EGCG, i.e. epigallocatechin gallate (EGCG), structural formula is as follows,
EGCG is a kind of native compound that extracting and developing obtains from green tea; it is the most efficient active monomer component in tea polyphenols; there is good safety and physiological activity widely; research shows; EGCG has antithrombus formation, arteriosclerosis, neuroprotective system, free radical resisting infringement, antioxidation, anti-oxidation stress, antiangiogenic, immunity moderation, protection cardiovascular and cerebrovascular vessel and antiinflammatory, antitumor, antiviral, antibacterial action, very important for health.
But disadvantageously, on the one hand, EGCG is more single in the mechanism of action for the treatment of cardiac and cerebral vascular diseases, lack the function of omnibearing protection cardiovascular and cerebrovascular vessel or treatment cardiovascular and cerebrovascular disease; On the other hand, the taste of EGCG is very pained, limits its application in medicine food, consumer or patient direct oral time be difficult to accept its bitter taste, the compliance making it apply is seriously restricted.
Folium Bambosae flavone; it is the biological flavone with physiologically active extracted from the Folium Bambusae of grass family Phyllostachys Ph. meyeri; it is a kind of biological anti-oxidant efficiently; it is the nutrient of needed by human; there are protection cardiovascular and cerebrovascular vessel; improve myocardial ischemia, improve cerebral ischemia, adjusting blood lipid; reduce the effect of blood viscosity; there is control cardiovascular and cerebrovascular disease; the function of antioxidation, antiinflammatory and immunity moderation; when human body lacks, easily cause the generation of the diseases such as heart and brain function are incomplete, sclerosis of blood vessels.
Summary of the invention
The discovery that inventor is pleasantly surprised, EGCG and Folium Bambosae flavone are combined, there is good synergism, especially in protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia etc. in synergism, and reducing the effect that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs; On the other hand, Folium Bambosae flavone can improve the bitter taste of EGCG, make consumer or patient direct oral time be easy to accept.
The object of this invention is to provide a kind of pharmaceutical composition containing EGCG and Folium Bambosae flavone, the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics.
Another object of the present invention is to provide the preparation method of above-mentioned composition;
The invention still further relates to the application of above-mentioned composition in medicine, medical usage.
The present composition comprises two kinds of compound modes:
A kind of compound mode is existed with the form of compound preparation EGCG and Folium Bambosae flavone, and the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics.Use corresponding pharmaceutical carrier or adjuvant, adopt different preparation technologies to can be made into different compound medicinal formulations.Be to be understood that, compound preparation refers to makes independent preparation using EGCG and Folium Bambosae flavone as medicament active composition, it can be any pharmaceutical dosage form that pharmaceutics can accept, preferred oral preparation, such as tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet, Deng), hard capsule (comprising enteric coated capsule), soft capsule, granule, powder, dry suspension, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, oral administration mixed suspension, and oral rapid release or the dosage form such as slow release or controlled release, or injection or cutaneous permeable agent, powder ampoule agent for injection (comprises Injectable sterile fill injectable powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator, also comprise the ointment of external preparation for skin, gel, emulsion agent, emulsion agent, patch, etc., also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing oral solution, tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), injection (comprising powder ampoule agent for injection and injection) that pharmaceutics uses.Preferred combination dosage form is oral formulations, most preferably oral granule, powder, dry suspension, tablet (comprise dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet, etc.), hard capsule (comprising enteric coated capsule), soft capsule, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, oral administration mixed suspension etc.
Another kind of compound mode is that EGCG and Folium Bambosae flavone are made independent preparation respectively, in use, patient can successively medication successively, also use after the preparation of the EGCG separated can being mixed with the preparation of Folium Bambosae flavone simultaneously, finally to reach the object using composition of medicine of the present invention, necessary, two kinds of independent preparations should be packaged in same drug package assembly by conveniently patient medication and represent the feature of drug regimen; Further, when EGCG and Folium Bambosae flavone are independent preparations, both pharmaceutical dosage forms can be identical, also can be different, as EGCG sheet and Folium Bambosae flavone tablet medicament composition, EGCG capsule and Folium Bambosae flavone pharmaceutical capsules compositions, EGCG sheet and Folium Bambosae flavone pharmaceutical capsules compositions, EGCG capsule and Folium Bambosae flavone tablet medicament composition, also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), granule, powder, dry suspension, pill, pellet (comprising enteric coated micropill), drop pill, dry syrup, powder, oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses.
Should be appreciated that or can give the present invention's compound of combination in turn simultaneously, these combination of compounds can be same or different pharmaceutical compositions.If administration in turn, the delay administration of the second active component should not reduce the effect of synergistic therapeutic action between this active ingredient combinations or collaborative drug mechanism.No matter simultaneously or administration in turn it is also understood that, EGCG and Folium Bambosae flavone can with independent or any combining form administrations, preferably by EGCG and Folium Bambosae flavone administration simultaneously or with the administration in turn of independent medicine type, and most preferably administration simultaneously.
Preferably give drug regimen of the present invention with compound preparation form, such as tablet, special in tablet is double-layer tablet, chewable tablet, capsule, granule, powder, dry suspension, oral solution, liquid preparation, medicinal tea for another example, etc.
Especially, the pharmaceutical composition containing EGCG and Folium Bambosae flavone provided by the invention, when pharmaceutical dosage form is the solid preparations such as tablet, capsule, granule, powder or dry suspension, wherein EGCG or Folium Bambosae flavone are the compositionss made with micronized form, preferred EGCG and Folium Bambosae flavone are pulverized by low-temperature airflow crushing technology, its powder size is greater than 800 orders, and preferred powder size is at 800 ~ 1000 orders, and even the granularity of preferred powder is greater than 1000 orders.
The present invention that another aspect of the present invention provides EGCG and Folium Bambosae flavone to exist with the ratio of synergistic drug dose combines.
Another aspect of the present invention provides EGCG and Folium Bambosae flavone with the combination of arbitrary proportion, and preferably with the present invention's combination that the ratio of synergistic dosage exists, EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.2 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.3 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.4 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.5 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.6 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.7 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.8 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1.9) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.15 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1.4) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1.3) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1.2) with weight ratio: the ratio combination of 1;
Concrete, such as preferably EGCG and Folium Bambosae flavone take weight ratio as 0.05:1,0.06:1,0.07:1,0.08:1,0.09:1,0.1:1,0.2:1,0.3:1,0.4:1,0.5:1,0.6:1,0.7:1,0.8:1,0.9:1,1:1,1.1:1,1.2:1,1.3:1,1.4:1,1.5:1,1.6:1,1.7:1,1.8:1,1.9:1,2:1, etc.
The oral applicable dosage of EGCG is generally adult's 50 ~ 1000mg level every day and gives this compound, preferred every day 100 ~ 800mg single or give this compound at twice, such as 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, the EGCG of 900mg or 1000mg, and give the Folium Bambosae flavone of effective dose, preferably give the Folium Bambosae flavone of 50 ~ 2000mg, such as 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, 900mg, 950mg, 1000mg, 1100mg, 1200mg, 1300mg, 1400mg, 1500mg, 1600mg, 1700mg, 1800mg, the Folium Bambosae flavone of 1900mg or 2000mg, etc..
Be to be understood that, the present invention contains the compositions of EGCG and Folium Bambosae flavone, optionally can also contain other medicines effect or food function composition, such as mannatide, lentinan, oligofructose, polyfructosan, oligomeric xylose, Oligomeric manna sugar, etc.
Preferably, the pharmaceutical composition of EGCG and Folium Bambosae flavone, wherein contains 50 ~ 1000mgEGCG and 50 ~ 2000mg Folium Bambosae flavone in preferred per unit preparation;
Concrete, containing 50mgEGCG and 50mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 50mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 160mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 100mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 150mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 550mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 650mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 750mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 850mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 950mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 200mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 250mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 100mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 150mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 200mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 250mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 300mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 350mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 400mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 450mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 600mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 700mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 800mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 900mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1000mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1100mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1200mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1300mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1400mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1500mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1600mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1700mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1800mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 1900mg Folium Bambosae flavone in per unit preparation,
Or containing 300mgEGCG and 2000mg Folium Bambosae flavone in per unit preparation,
Or containing 350mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 400mgEGCG and 500mg Folium Bambosae flavone in per unit preparation,
Or containing 500mgEGCG and 500mg Folium Bambosae flavone in per unit preparation.
Described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, comprise each seed lac wafer, each tablet or pill, each bag of granule or powder, each bottle of oral administration solution, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment, etc.
Usually can give the active component of drug regimen with chemical raw material form, but preferably give with Pharmaceutical composition form.Pharmaceutical composition of the present invention comprises EGCG and Folium Bambosae flavone, and the drug regimen of the present invention of one or more pharmaceutically acceptable carriers or excipient.These carriers must be acceptable, can with other component compatibility of formula, and nontoxic to its receiver.When giving separately each component of said composition, they are each form of Pharmaceutical composition naturally generally.Unless otherwise indicated, the compositions of indication of the present invention refers to the drug regimen containing EGCG and Folium Bambosae flavone, or the compositions of the wherein drug regimen of each component of EGCG and Folium Bambosae flavone.
Preferably, the combination of EGCG and Folium Bambosae flavone is generally the Pharmaceutical composition with one or more pharmaceutically acceptable carriers of unit dosage form, and the EGCG contained in conventional unit formulation and the dosage of Folium Bambosae flavone are clear and definite in the foregoing.
Use corresponding, different pharmaceutical carriers and preparation technology, pharmaceutical composition of the present invention can be made different pharmaceutical dosage forms.What those skilled in the art were appreciated that is, these pharmaceutical carriers be become various dosage form for the ease of production and processing, guarantee medicine safe, effectively with the factor such as to stablize, and to select according to the physicochemical property of different pharmaceutical dosage forms and medicine self.The choice for use of pharmaceutical carrier is that those of skill in the art of the present invention know with apparent.
Be to be understood that, for oral or injection, according to method well known in the art, usually according to the pharmaceutical carrier that different medicaments is selected or combinationally used, optionally comprise excipient or diluent, such as microcrystalline Cellulose, mannitol, non-dairy creamer, lactose, pregelatinized Starch, starch, dextrin, cyclodextrin, maltodextrin, HP-β-CD, calcium phosphate, calcium hydrogen phosphate, hydroxypropyl emthylcellulose, sucrose, dextran, poloxamer, sodium chloride, sorbitol, glucose, oligofructose, polyfructosan, oligomeric xylose, polydextrose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), resistant dextrin, fructose, water, propylene glycol, glycerol, coffee, milk powder, vegetable protein powder, etc., for oral solid formulation, optionally can also comprise binding agent, such as polyvidone (polyvinylpyrrolidone), methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, pregelatinized Starch, carboxymethyl starch sodium, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, etc., also comprise lubricant, such as magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate, sodium lauryl sulphate, etc., also optionally comprise disintegrating agent, such as carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, pregelatinized Starch, etc., also optionally comprise surfactant or cosolvent, such as sodium lauryl sulphate, Tween-80, etc., also can comprise pH value regulator or buffer agent or cosolvent, such as phosphate buffer, citric acid, sodium citrate, acetate buffer, dilute hydrochloric acid, lactic acid, sodium carbonate, sodium hydroxide, alkaline organic compound, as arginine, lysine, meglumine, trometamol, etc., also optionally comprise antiseptic, such as sodium benzoate, potassium sorbate, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, etc., also optionally comprise stabilizing agent and antioxidant, such as metal chelating agent selects ethylenediaminetetraacetic acid and salt (calcium disodium edetate, disodium edetate) etc. thereof, sodium sulfite, sodium pyrosulfite, vitamin C, vitamin E, etc., also optionally comprise taste regulator, such as maltose alcohol, fructose, sucrose, saccharin sodium, flavoring orange essence, strawberry essence, etc., that also can comprise other routine in addition, appropriate additive.It is also understood that agent type be tablet or capsule time, can be film coating.For the material of film coating, comprise applicable coating materials, such as hydroxypropyl methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate (enteric-coating material), etc.; Also can comprise plasticizer, such as Polyethylene Glycol, triethyl citrate, etc.; Also optionally comprise suitable solubilizing agent, as Polyoxyethylene Sorbitan Monooleate; Also can comprise suitable pigment, as titanium dioxide, various ferrum oxide, pink pigment, etc.Should be appreciated that above-mentioned " optionally comprising " refers to namely can optionally choice for use, also can not use.
Especially, the compositions of EGCG of the present invention and Folium Bambosae flavone, EGCG can be different on medicament releasing pattern from the chemical composition of Folium Bambosae flavone, such as EGCG can the form of slow release or controlled release occur, and Folium Bambosae flavone also can the form of slow release or controlled release occur, to improve the not synergism of the blood drug level that EGCG and the time difference of Folium Bambosae flavone in onset or metabolism cause.
In the present patent application, " compositions " refers to described EGCG or/and Folium Bambosae flavone, with other chemical composition, such as, on physiology/mixture that formed of pharmaceutically acceptable carrier or excipient, the object of pharmaceutical composition is conducive to the using of medicine, carries, preserves; " administration " mentioned here refer in order to prevent or disease therapy and to organism (comprising patient or healthy population) deliver described in compound, its pharmaceutically useful salt or its solvate; Described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, as each bottle of oral administration solution, each capsules, each tablet or pill, each bag of granule or powder, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment, etc.
On the other hand; have now found that; when EGCG and Folium Bambosae flavone combinationally use; it demonstrates unexpected advantage; especially this drug regimen demonstrate outstanding, beyond thought in protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia etc. in synergism, and there is the risk etc. that myocardial infarction, apoplexy or cardiovascular disease cause there is good synergistic function reducing.Preferably; the pharmaceutical composition of EGCG of the present invention and Folium Bambosae flavone; for the preparation of protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia, the application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, etc.
Therefore, on the other hand, the invention provides a kind of protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia, or reduce the pharmaceutical composition that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, it contains EGCG and Folium Bambosae flavone.It will be appreciated by those skilled in the art that, in its pharmaceutical composition, the dosage ratio in the compound mode of EGCG and Folium Bambosae flavone, per unit preparation and content, just the same with the aforesaid content of the present invention.
Further, present invention also offers the preparation method of the pharmaceutical composition of EGCG and Folium Bambosae flavone, it comprises and EGCG and Folium Bambosae flavone is mixed with pharmaceutically acceptable pharmaceutical carrier and make acceptable any pharmaceutical preparation on pharmaceutics, such as EGCG and Folium Bambosae flavone and pharmaceutical carrier dry powder blend, dry granulation mixing (dry granulating machine process), wet granulation mixing (with water or alcoholic solution wet granulation), liquid or semisolid mixes (as the content of soft capsule, drop pill dropping liquid mixes) etc., preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet etc.), hard capsule (comprising enteric coated capsule), granule, dry suspension, oral solution, dry syrup, powder, oral administration mixed suspension, soft capsule, pill, pellet (comprising enteric coated micropill), drop pill, and oral rapid release or the dosage form such as slow release or controlled release, powder ampoule agent for injection (comprises Injectable sterile fill powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator, also can be the rapid releases of above various dosage form, slow release, the dosage forms such as controlled release, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, born of the same parents rise granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses; Or
The preparation method of the pharmaceutical composition of the EGCG that the present invention also provides and Folium Bambosae flavone, it comprises EGCG and Folium Bambosae flavone is mixed and made into independent pharmaceutical preparation with pharmaceutically acceptable pharmaceutical carrier respectively, and by two kinds of independent pharmaceutical preparation packages in same medicine box, preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, enteric coatel tablets, chewable tablet, oral cavity disintegration tablet, effervescent tablet etc.), hard capsule (comprising enteric coated capsule), granule, dry suspension, dry syrup, powder, soft capsule, oral solution, pill, pellet (comprising enteric coated micropill), drop pill, oral administration mixed suspension, and oral rapid release or the dosage form such as slow release or controlled release, powder ampoule agent for injection (comprises Injectable sterile fill powder, lyophilized injectable powder), aqueous solution injection, injection can also be with glucose, sodium chloride, fructose, Nulomoline, xylitol or maltose etc. use the aqueous solution of (comprising intravenous injection and intravenous drip) as the intravenous injection of osmotic pressure regulator.Also can be the dosage form such as rapid release, slow release, controlled release of above various dosage form, such as oral dispersible tablet, slow releasing tablet, slow releasing capsule, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets, effervescent granule, etc.Especially, by means known in the art preparation, be preferred for preparing tablet (comprising dispersible tablet, slow-release tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets), capsule (comprising gastric solubleness, enteric, slow releasing capsule), oral solution, injection (comprising powder ampoule agent for injection and injection) etc. that pharmaceutics uses.
Preferably, the invention provides a kind of granule containing EGCG and Folium Bambosae flavone, described EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.1 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.2 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.3 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.4 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.5 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.6 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.7 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (1.8 ~ 2) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.06 ~ 1.9) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.07 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.08 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.09 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.1 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.15 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.2 ~ 1.8) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.3 ~ 1.7) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.4 ~ 1.6) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.5 ~ 1.5) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.6 ~ 1.4) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.7 ~ 1.3) with weight ratio: the ratio combination of 1,
Preferred EGCG and Folium Bambosae flavone are (0.8 ~ 1.2) with weight ratio: the ratio combination of 1;
Concrete, such as preferably EGCG and Folium Bambosae flavone take weight ratio as 0.05:1,0.06:1,0.07:1,0.08:1,0.09:1,0.1:1,0.2:1,0.3:1,0.4:1,0.5:1,0.6:1,0.7:1,0.8:1,0.9:1,1:1,1.1:1,1.2:1,1.3:1,1.4:1,1.5:1,1.6:1,1.7:1,1.8:1,1.9:1,2:1, etc.;
Also containing granule adjuvant in described granule composite, described granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, wherein the content of granule adjuvant is greater than 30% with mass ratio range, and the content of preferred particulates agent adjuvant is greater than 45% with mass ratio range, and the content of preferred particulates agent adjuvant is greater than 60% with mass ratio range,
Further, the invention provides a kind of preparation method containing the granule of EGCG and Folium Bambosae flavone, it comprises: EGCG, Folium Bambosae flavone are mixed homogeneously with granule adjuvant respectively, use ethanol water wet granulation again, dry, granulate, wherein the content of granule adjuvant is greater than 30% with mass ratio range; Especially, the invention provides a kind of preparation method containing EGCG and Folium Bambosae flavone granule, it comprises:
(1) prepare burden: take EGCG, Folium Bambosae flavone by formula, first EGCG is added mix homogeneously in granule adjuvant, then add Folium Bambosae flavone mix homogeneously, preferably adopt equal increments hybrid mode to carry out mix homogeneously;
(2) granulate: by the material 75% alcoholic solution soft material prepared in (1), wet granulation, 45 ~ 70 DEG C of dryings, granulate;
(3) pack, check, obtain the granule that the present invention contains EGCG and Folium Bambosae flavone.
Further, above-mentioned granule fill can be obtained capsule in Capsules shell, or above-mentioned granule is pressed into tablet by tablet forming technique.
Further, the present invention also provides the compositions application below of EGCG and Folium Bambosae flavone:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Synergism in waiting, Yi Ji
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs, etc.
The compositions of EGCG of the present invention and Folium Bambosae flavone, has the advantage of following three aspects:
1, Folium Bambosae flavone has special taste, is similar to the slight bitterness of Chinese medicine and has back sugariness, can improve the bitter taste of EGCG well, makes oral person be easy to accept;
3, the compositions of EGCG and Folium Bambosae flavone protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve synergism in cardiac-cerebral ischemia etc.; and occur to there is good synergistic function, for comparatively comprehensively preventing and treating cardiovascular and cerebrovascular disease advantageously in the risk that causes of myocardial infarction, apoplexy or cardiovascular disease etc. reducing.
detailed description of the inventionin implementation process of the present invention, those of ordinary skill in the art are not departing from the scope of the present invention various embodiment that the basis with spirit produces and are modifying apparent and be easily carry out.By the following examples application of the present invention etc. done and illustrate further, but do not represent embodiment limitation of the present invention.
The compound tablet of embodiment 1, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 5% ~ 25%, is preferably 15%,
Folium Bambosae flavone 10% ~ 40%, is preferably 30%,
Mannitol 20% ~ 35%, is preferably 30%,
Calcium hydrogen phosphate 8% ~ 20%, is preferably 17%,
Carboxymethyl starch sodium 1% ~ 10%, is preferably 5%,
Hydroxypropyl cellulose aqueous solution is appropriate, and preferably 2.5% hydroxypropyl cellulose aqueous solution, counts 2% with hydroxypropyl cellulose,
Magnesium stearate 0.5% ~ 2%, is preferably 1%;
Its preparation method comprises: by EGCG, Folium Bambosae flavone, mannitol, calcium hydrogen phosphate, carboxymethyl starch sodium crosses 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first by EGCG and mannitol mix homogeneously, obtain A mixed-powder, another by Folium Bambosae flavone and calcium hydrogen phosphate mix homogeneously, obtain B mixed-powder, then by A mixed-powder, after B mixed-powder is mixed homogeneously with carboxymethyl starch sodium, add 2.5% hydroxypropyl cellulose aqueous solution and make soft material, cross 24 mesh sieves to granulate, after 45 ~ 60 DEG C of dryings, 20 mesh sieve granulate, add the magnesium stearate of recipe quantity, mixing, tabletting, obtain.
The compound granule of embodiment 2, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 1% ~ 10%, is preferably 3%,
Folium Bambosae flavone 1% ~ 20%, is preferably 10%,
Granule adjuvant 85% ~ 98%, is preferably fructose 87%;
Wherein said granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol (such as PEG-4000, Polyethylene Glycol-12000, PEG-4000, Polyethylene glycol-2000 etc.), dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, most preferably be fructose or/and oligofructose, polyfructosan,
Its preparation method comprises: EGCG, Folium Bambosae flavone, granule adjuvant are crossed 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first EGCG is mixed homogeneously with granule adjuvant, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.Further, above-mentioned granule fill can be obtained capsule in Capsules shell, or above-mentioned granule is pressed into tablet by tablet forming technique.
The compound capsule of embodiment 3, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 10% ~ 30%, is preferably 15%,
Folium Bambosae flavone 15% ~ 45%, is preferably 40%,
Mannitol 15% ~ 35%, is preferably 26%,
Pregelatinized Starch 8% ~ 25%, is preferably 12%,
Carboxymethyl starch sodium 1% ~ 15%, is preferably 5%,
The alcoholic solution of polyvinylpyrrolidone is appropriate, preferably with polyvinylpyrrolidone for 1%,
Magnesium stearate 0.5% ~ 2%, is preferably 1%;
Its preparation method comprises: EGCG, Folium Bambosae flavone, mannitol, pregelatinized Starch, carboxymethyl starch sodium are crossed 80 mesh sieves respectively, and preferred mistake 100 mesh sieve, after taking, first by EGCG and Folium Bambosae flavone mix homogeneously, obtains A mixed-powder by recipe quantity, stand-by; Another by mannitol, pregelatinized Starch, carboxymethyl starch sodium mix homogeneously, obtain B mixed-powder, then A mixed-powder is fully mixed homogeneously with B mixed-powder, the alcoholic solution adding polyvinylpyrrolidone makes soft material, crosses 20 mesh sieves and granulates, 45 ~ 70 DEG C of oven dry, dry granule crosses 18 mesh sieve granulate, add magnesium stearate mix homogeneously, be filled to capsulae vacuus, to obtain final product.
The compound granule of embodiment 4, EGCG and Folium Bambosae flavone and preparation thereof
Recipe quantity by weight percentage, contains:
EGCG 1% ~ 6%, is preferably 2%,
Folium Bambosae flavone 1% ~ 10%, is preferably 8%,
Maltodextrin 3% ~ 10%, is preferably 5%,
Other granule adjuvant 75% ~ 95%, is preferably fructose 85%;
Other granule adjuvant wherein said comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline (i.e. the equal amount of mixture of glucose and fructose), glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, most preferably be fructose or/and oligofructose, polyfructosan,
Its preparation method comprises: EGCG, Folium Bambosae flavone, maltodextrin, other granule adjuvant are crossed 80 mesh sieves respectively, preferred mistake 100 order, after taking by recipe quantity, first EGCG is mixed homogeneously with maltodextrin, other granule adjuvant successively, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
The compositions of embodiment 5, EGCG and Folium Bambosae flavone is improving the effect in myocardial ischemia
Animal: SD rat, male and female half and half, body weight 160 ~ 190g.
Myocardial infarction and ischemia model: get rat urethane intraperitoneal injection of anesthesia, lie on the back and be fixed on operating-table, expose trachea, open front and plug in respirator, on the left of breastbone, 3,4 rib places open breast, expose heart, with operation needle threading ligation left coronary artery between left auricle root and pulmonary artery circular cone, close thoracic cavity, form myocardial infarction and ischemia model.
Experimental technique: rat is divided into model control group at random, administration group, wherein administration group gives oral administration gavage EGCG 6mg/kg respectively on normal feed basis, Folium Bambosae flavone 12mg/kg, the compositions l0mg/kg of EGCG and Folium Bambosae flavone weight ratio 1:2, each administration group successive administration is after 3 days, myocardial infarction and ischemia model is carried out in the 4th day, oral administration gavage EGCG 6mg/kg is given respectively after modeling success, Folium Bambosae flavone 12mg/kg, the compositions l2mg/kg of EGCG and Folium Bambosae flavone (weight ratio 1:2), 180min after administration, take off heart immediately, with normal saline flushing, weigh heavy (g) whole-heartedly, atrium and each trunk is cut off along coronary sulcus, satisfactory room heavy (g), ventricle is placed in after refrigerator and cooled freezes, below heart ligature, be parallel to arteria coronaria ditch and be cut into 5 by cross-section for ventricular section equably, the thick about 1 ~ 2mm of every sheet, the weight of 5 is the weight (g) of pricking inferior segment, then nitro blue tetrazolium (N-BT) dye liquor is placed in, take out after constant temperature dyeing 15min in 37 DEG C of water baths, normal myocardium dye is skipper, infarcted region cardiac muscle is then not painted or light yellow.Draw the infarcted region on every sheet cardiac muscle two sides, non-infarcted region and cavity scope.Use paper-cut method, measure every sheet cardiac muscle infarcted region on two sides and the weight (mg) of normal myocardium, the gross weight weighing up 5 is ventricle gross weight (mg).Calculate the myocardial infarction percentage ratio (%) of infarcted region, ventricle group infarcted region, bundle inferior segment infarcted region whole-heartedly respectively, compare between group with t inspection, the results are shown in Table 1.
The compositions of table 1 EGCG and Folium Bambosae flavone is on the impact of rats with myocardial ischemia myocardial infarct size
( ,%,n=8)
Conclusion: the compositions of EGCG of the present invention and Folium Bambosae flavone, in the animal model of SD myocardial ischemia in rats, significantly can reduce infarct size, shows good improvement myocardial ischemia, the effect of protecting myocardial cell; Relative to model control group, the compositions group of EGCG and Folium Bambosae flavone has highly significant difference, p<0.01; Relative to Folium Bambosae flavone group and EGCG group, also there is very significant difference, p<0.05.Demonstrate pharmaceutical composition of the present invention at the outstanding role improving myocardial ischemia, protecting myocardial cell.
The compositions of embodiment 6, EGCG and Folium Bambosae flavone is to the protective effect of cerebral ischemia-reperfusion neural cell injury
Employing is closed folder middle cerebral artery and is made specific region, local acute cerebral ischemia in rats model; calculate dead neuronal cell number; observe neuronic morphological change, from the compositions of cell and Molecular level study EGCG and Folium Bambosae flavone in neuroprotective unit and the effect preventing and treating cerebral ischemia.
Method: Wistar rat, body weight 150 ~ 200g, male and female half and half, random packet, is divided into model group, EGCG administration group, Folium Bambosae flavone administration group, EGCG and Folium Bambosae flavone compositions administration group, often organizes 8.
First to rats underwent 10% chloral hydrate anesthesia (ip, 350mg.Kg -1) after, carefully pry open skull with apparatus, expose and close folder middle cerebral artery and cause specific region, local acute cerebral ischemia model, to close folder middle cerebral artery side for ischemia side (experimental group), opposite side does not close folder (matched group) in contrast.
Each group of equal capable intraperitoneal injection drug of 30min before ischemia.All specimen all have drawn from representational relevant range, and fix through 4% neutral formalin rapidly, conventional dehydration, paraffin embedding, HE dyeing and HSP70 dyeing.Occur karyopycnosis with neuronal cell, karyorrhexis after HE dyeing, karyolysis person is judged to neuronal death, gets 5 high power lens visuals field often opening in section, and statistics dead cell accounts for the percentage ratio of total cell, gets its meansigma methods.
HSP70 is the one in HSP family, and molecular weight is 70KDa, and its major function is that protection is various stress caused cell injury and apoptosis, and induction HSP70 high expressed can alleviate the neuronal damage caused by cerebral ischemia.
Experiment grouping:
(1) model group: intraperitoneal injection equal-volume distilled water;
(3) EGCG administration group: the isopyknic EGCG distilled water solution of intraperitoneal injection, EGCG dosage 5mg/kg;
(4) Folium Bambosae flavone administration group: the isopyknic Folium Bambosae flavone distilled water solution of intraperitoneal injection, Folium Bambosae flavone dosage 12mg/kg;
(5) EGCG and Folium Bambosae flavone compositions administration group: the distilled water solution of the isopyknic EGCG of intraperitoneal injection and Folium Bambosae flavone compositions (weight ratio 1:2.4), EGCG and Folium Bambosae flavone compositions dosage 12mg/kg.
Result: in table 2.
The compositions of table 2 EGCG and Folium Bambosae flavone changes cerebral morphology, the expression (n=8) of nerve cell death rate and HSP70
As can be seen from Table 2; the compositions of EGCG and Folium Bambosae flavone has good protective effect for rat cerebral ischemia; and protection cerebral tissue, neuroprotective cell, alleviate cerebral tissue edema degree; in nerve cell death rate, HSP70 expression data; compared with independent EGCG administration group, Folium Bambosae flavone administration group; there is significant difference, p<0.05.Show the present composition in the effect protecting cardiovascular and cerebrovascular vessel, protect heart and brain tissues, improve cardiac-cerebral ischemia, protect heart and brain cell.
The compositions of embodiment 7, EGCG and Folium Bambosae flavone is to the effect of bitter taste improving EGCG
Get EGCG and Folium Bambosae flavone weight ratio is the compositions of 1:0.5,1:1,1:1.5,1:2, carry out bitter taste and compare.
The preparation of bitter taste reference material: be the former powder of EGCG and the mixed uniformly powder of maltodextrin of 0,10%, 30%, 50%, 70%, 90% respectively with the addition of maltodextrin, respectively get 5g, add 45 DEG C of hot water of 100ml, abundant dissolving, tastes, obtains the bitter taste reference material that bitter taste degree is labeled as 10.0 points, 9.0 points, 7.0 points, 5.0 points, 3.0 points, 1.0 points respectively, be up to 10.0 points, retain an arithmetic point, score value is higher, characterizes bitter taste larger.
Bitter taste comparative approach: based on bitter taste reference material, by the trial test method of 5 people to testing combination bitter taste, compare with bitter taste reference material, differentiate, testing combination bitter taste is given a mark and (is up to 10.0 points, retain an arithmetic point), average, be used for comparing, the bitter taste of compositions relatively more prepared respectively.
Bitter taste compares the following table 3 of data.
Table 3
As can be seen from 3 tables, the compositions of EGCG of the present invention and Folium Bambosae flavone, compare with the former powder of EGCG, bitter taste significantly declines, and along with the increase of Folium Bambosae flavone content in the composition, the decline of its bitter taste is more; EGCG and Folium Bambosae flavone weight ratio are the compositions of 1:0.5,1:1, its bitter taste only has about 60 percent (p<0.05) of the former powder of EGCG, EGCG and Folium Bambosae flavone weight ratio are the compositions of 1:1.5,1:2, and its bitter taste is all less than 50 percent (p<0.01) of the former powder of EGCG; Demonstrate the present composition, to the bitter taste improving EGCG, there is remarkable effect.
The application in following of the compositions of embodiment 8, EGCG described in embodiment 1 to embodiment 4 and Folium Bambosae flavone:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs.

Claims (10)

1. contain the pharmaceutical composition of EGCG and Folium Bambosae flavone, the dosage form of described medicine is any pharmaceutical dosage form of acceptable on pharmaceutics, its compound mode comprises: EGCG and Folium Bambosae flavone are made compound preparation, or EGCG and Folium Bambosae flavone are made independent preparation respectively, and two kinds of independent preparations are packaged in same drug package assembly.
2. contain the pharmaceutical composition of EGCG and Folium Bambosae flavone, wherein said EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1.
The pharmaceutical composition of 3.EGCG and Folium Bambosae flavone, wherein contain 50 ~ 1000mgEGCG and 50 ~ 2000mg Folium Bambosae flavone in per unit preparation, described " per unit preparation " refers to the preparation unit of minimum package or minimum form of medication, comprises each seed lac wafer, each tablet or pill, each bag of granule or powder, each bottle of oral administration solution, each injection or injection, each bottle of injection or injection, each piece of suppository, each bottle of eye drop, each pipe ointment.
4. the pharmaceutical composition preparation method containing EGCG and Folium Bambosae flavone that described in claim 1 to claim 3, any one contains, it comprises and EGCG and Folium Bambosae flavone is mixed with pharmaceutically acceptable pharmaceutical carrier and make acceptable any pharmaceutical preparation on pharmaceutics.
5. one kind contains the granule of EGCG and Folium Bambosae flavone, described EGCG and Folium Bambosae flavone are (0.05 ~ 2) with weight ratio: the ratio combination of 1, also containing granule adjuvant in described granule composite, wherein granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, wherein the content of granule adjuvant is greater than 30% with mass ratio range, the preparation method of described granule comprises:
(1) prepare burden: take EGCG, Folium Bambosae flavone by formula, first EGCG is added mix homogeneously in granule adjuvant, then add Folium Bambosae flavone mix homogeneously;
(2) granulate: by the material 75% alcoholic solution soft material prepared in (1), wet granulation, 45 ~ 70 DEG C of dryings, granulate;
(3) pack, check, to obtain final product.
6. a compound tablet for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 5%~25%,
Folium Bambosae flavone 10% ~ 40%,
Mannitol 20% ~ 35%,
Calcium hydrogen phosphate 8% ~ 20%,
Carboxymethyl starch sodium 1% ~ 10%,
Hydroxypropyl cellulose aqueous solution is appropriate,
Magnesium stearate 0.5% ~ 2%;
Its preparation method comprises: by EGCG, Folium Bambosae flavone, mannitol, calcium hydrogen phosphate, carboxymethyl starch sodium crosses 80 mesh sieves respectively, after taking by recipe quantity, first by EGCG and mannitol mix homogeneously, obtain A mixed-powder, another by Folium Bambosae flavone and calcium hydrogen phosphate mix homogeneously, obtain B mixed-powder, then by A mixed-powder, after B mixed-powder is mixed homogeneously with carboxymethyl starch sodium, add 2.5% hydroxypropyl cellulose aqueous solution and make soft material, cross 24 mesh sieves to granulate, after 45 ~ 60 DEG C of dryings, 20 mesh sieve granulate, add the magnesium stearate of recipe quantity, mixing, tabletting, obtain.
7. a compound granule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 1%~10%
Folium Bambosae flavone 1% ~ 20%,
Granule adjuvant 85% ~ 98%;
Wherein said granule adjuvant comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, maltodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, its preparation method comprises: EGCG, Folium Bambosae flavone, granule adjuvant are crossed 80 mesh sieves respectively, after taking by recipe quantity, first EGCG is mixed homogeneously with granule adjuvant, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
8. a compound capsule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 10%~30%,
Folium Bambosae flavone 15% ~ 45%,
Mannitol 15% ~ 35%,
Pregelatinized Starch 8% ~ 25%,
Carboxymethyl starch sodium 1% ~ 15%,
The alcoholic solution of polyvinylpyrrolidone is appropriate,
Magnesium stearate 0.5% ~ 2%;
Its preparation method comprises: EGCG, Folium Bambosae flavone, mannitol, pregelatinized Starch, carboxymethyl starch sodium are crossed 80 mesh sieves respectively, after taking, first by EGCG and Folium Bambosae flavone mix homogeneously, obtains A mixed-powder by recipe quantity, stand-by; Another by mannitol, pregelatinized Starch, carboxymethyl starch sodium mix homogeneously, obtain B mixed-powder, then A mixed-powder is fully mixed homogeneously with B mixed-powder, the alcoholic solution adding polyvinylpyrrolidone makes soft material, crosses 20 mesh sieves and granulates, 45 ~ 70 DEG C of oven dry, dry granule crosses 18 mesh sieve granulate, add magnesium stearate mix homogeneously, be filled to capsulae vacuus, to obtain final product.
9. a compound granule for EGCG and Folium Bambosae flavone, its recipe quantity by weight percentage, contains:
EGCG 1%~6%,
Folium Bambosae flavone 1% ~ 10%,
Maltodextrin 3% ~ 10%,
Other granule adjuvant 75% ~ 95%;
Other granule adjuvant wherein said comprises one or more compositions following: fructose, xylitol, oligofructose, polyfructosan, oligomeric xylose, polydextrose, mannitol, sucrose, Nulomoline, glucose, resistant dextrin, Sorbitol, maltose, hydroxyl isomaltulose, Oligomeric manna sugar, solid polyethylene glycol, dextrin, cyclodextrin, HP-β-CD, microcrystalline Cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, pregelatinized Starch, starch, starch sugar, lactose, non-dairy creamer, milk powder, vegetable protein powder, coffee, carboxymethyl starch sodium, protein sugar, sucralose, aspartame, acesulfame potassium, stachyose, neotame, steviol glycosides, its preparation method comprises: EGCG, Folium Bambosae flavone, maltodextrin, other granule adjuvant are crossed 80 mesh sieves respectively, after taking by recipe quantity, first EGCG is mixed homogeneously with maltodextrin, other granule adjuvant successively, then after adding Folium Bambosae flavone mix homogeneously, with 75% alcoholic solution wet granulation, 45 ~ 70 DEG C of dryings, granulate packaging, inspection, to obtain final product.
10. any one described in claim 1 to claim 3, claim 5 to claim 9 contain EGCG and Folium Bambosae flavone the application of pharmaceutical composition in following:
Preparation protection cardiovascular and cerebrovascular vessel, protect heart and brain tissues, the application improved in the medicine of cardiac-cerebral ischemia;
Application in preparation reduces the medicine that the risk that myocardial infarction, apoplexy or cardiovascular disease cause occurs.
CN201510228678.XA 2015-05-07 2015-05-07 Composition of EGCG and bamboo-leaves flavones and its preparation method and application Active CN104825873B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510228678.XA CN104825873B (en) 2015-05-07 2015-05-07 Composition of EGCG and bamboo-leaves flavones and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510228678.XA CN104825873B (en) 2015-05-07 2015-05-07 Composition of EGCG and bamboo-leaves flavones and its preparation method and application

Publications (2)

Publication Number Publication Date
CN104825873A true CN104825873A (en) 2015-08-12
CN104825873B CN104825873B (en) 2018-06-12

Family

ID=53804317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510228678.XA Active CN104825873B (en) 2015-05-07 2015-05-07 Composition of EGCG and bamboo-leaves flavones and its preparation method and application

Country Status (1)

Country Link
CN (1) CN104825873B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105614869A (en) * 2016-02-14 2016-06-01 王保红 Composition containing Cordyceps militaris and preparation method and application thereof
CN105831244A (en) * 2016-03-30 2016-08-10 浙江科技学院 Microencapsulation liquid for controlling yoghourt post-acidification and method for controlling yoghourt post-acidification
CN105962339A (en) * 2016-05-09 2016-09-28 山东康富森生物科技有限公司 Bamboo-leaf flavone catechin tablets and preparation method thereof
CN108077699A (en) * 2018-02-07 2018-05-29 聂聪忠 A kind of composition and its beverage and preparation method for the nourishing the stomach that sterilizes
CN108743825A (en) * 2018-06-28 2018-11-06 广东南方洁灵科技实业有限公司 A kind of composition for oral cavity and its preparation method and application containing bamboo-leaves flavones
CN109315576A (en) * 2018-10-12 2019-02-12 肖文中 Natto bamboo-leaves flavones pressed candy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005082495A (en) * 2003-09-04 2005-03-31 Pharma Foods International Co Ltd Cerebral cell-protecting composition
US20100040696A1 (en) * 2008-08-12 2010-02-18 Ilse Sente Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same
CN104587260A (en) * 2015-01-28 2015-05-06 福州乾正药业有限公司 Composition of bamboo leaf flavonoid and chitosan oligosaccharide, as well as preparation method and application thereof
CN104587266A (en) * 2015-02-05 2015-05-06 福州乾正药业有限公司 Composition of nervonic acid and bamboo leaf flavonoid as well as preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005082495A (en) * 2003-09-04 2005-03-31 Pharma Foods International Co Ltd Cerebral cell-protecting composition
US20100040696A1 (en) * 2008-08-12 2010-02-18 Ilse Sente Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same
CN104587260A (en) * 2015-01-28 2015-05-06 福州乾正药业有限公司 Composition of bamboo leaf flavonoid and chitosan oligosaccharide, as well as preparation method and application thereof
CN104587266A (en) * 2015-02-05 2015-05-06 福州乾正药业有限公司 Composition of nervonic acid and bamboo leaf flavonoid as well as preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
葛建等: ""表没食子儿茶素没食子酸酯(EGCG)生物活性研究进展"", 《安徽农业大学学报》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105614869A (en) * 2016-02-14 2016-06-01 王保红 Composition containing Cordyceps militaris and preparation method and application thereof
CN105831244A (en) * 2016-03-30 2016-08-10 浙江科技学院 Microencapsulation liquid for controlling yoghourt post-acidification and method for controlling yoghourt post-acidification
CN105831244B (en) * 2016-03-30 2019-09-24 浙江科技学院 A kind of the microencapsulation liquid and control post-acidification of yoghurt method of control post-acidification of yoghurt
CN105962339A (en) * 2016-05-09 2016-09-28 山东康富森生物科技有限公司 Bamboo-leaf flavone catechin tablets and preparation method thereof
CN108077699A (en) * 2018-02-07 2018-05-29 聂聪忠 A kind of composition and its beverage and preparation method for the nourishing the stomach that sterilizes
CN108743825A (en) * 2018-06-28 2018-11-06 广东南方洁灵科技实业有限公司 A kind of composition for oral cavity and its preparation method and application containing bamboo-leaves flavones
CN109315576A (en) * 2018-10-12 2019-02-12 肖文中 Natto bamboo-leaves flavones pressed candy

Also Published As

Publication number Publication date
CN104825873B (en) 2018-06-12

Similar Documents

Publication Publication Date Title
CN104825873B (en) Composition of EGCG and bamboo-leaves flavones and its preparation method and application
CN104922145B (en) Composition of γ-aminobutyric acid and chitosan oligosaccharide and its preparation method and application
CN104587260B (en) The composition of bamboo-leaves flavones and chitosan oligosaccharide, its preparation method and application
CN104587266B (en) The composition of nervonic acid and bamboo-leaves flavones, its preparation method and application
CN104739848A (en) Composition containing L-arabinose and tagatose as well as preparation method and drug application of composition
AU2017317950B2 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
CN110327374B (en) A pharmaceutical composition prepared from maggot for preventing and/or treating convulsion
CN104721230A (en) Composite of milk basic protein and milk mineral, preparation method thereof and application
CN104922143B (en) The composition and its preparation method and application of EGCG and chitosan oligosaccharide
CN105326053A (en) L-carnitine and chitosan oligosaccharide-containing composition and preparation method and application
CN104784197A (en) EGCG and beta-glucan composition, and preparation method, and medical application thereof
CN103690955B (en) Pharmaceutical composition containing ticagrelor and preparation method thereof and medicinal application
CN104840800B (en) Bamboo-leaves flavones and the composition of γ-aminobutyric acid and its preparation method and application
CN104825441A (en) EGCG and gamma-aminobutyric acid composition, and preparation method and applications thereof
CN101632659A (en) Medicinal composition of antiviral medicament and pidotimod, preparation method thereof and medicinal application thereof
CN109589323A (en) Nervonic acid and the solid dispersion composition of EGCG and its preparation method and application
CN103735552B (en) Pharmaceutical composition of ticagrelor and cilostazol and its preparation method and application
US7867524B2 (en) Energizing formulation
CN103859395A (en) Self-emulsifying drug release system of coenzyme Q10 with high absorptivity and preparation method and application thereof
CN104739776A (en) Solid dispersion composition of levocarnitine as well as preparation method and medical application of solid dispersion composition
CN103735551B (en) Pharmaceutical composition of cardiovascular and cerebrovascular vessel and its preparation method and application
CN106943390B (en) Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament
JPH02152926A (en) Brain edema depressant
WO2016086776A1 (en) Antifungal compound formulation containing chlorogenic acid and application thereof
US20220347121A1 (en) Methods of preparing compositions containing thymoquinone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231030

Address after: 430000 East Floor, Building C4, Biological Innovation Park, No. 666 Gaoxin Avenue, Handong Lake New Technology Development Zone, Wuhan City, Hubei Province

Patentee after: Hubei Chang'e Biological Co.,Ltd.

Address before: 350008 Jinshan Industrial Concentration Zone, 6 Lane Road, Jianxin Town, Cangshan District, Fuzhou, Fujian, two, Cangshan, 25.

Patentee before: FUZHOU QIANZHENG PHARMACEUTICAL Co.,Ltd.